EIT Health, a network of best-in-class innovators backed by the EU, has announced the second year of its innovation programme, Wild Card. The second year of high-risk innovation programme Wild Card kicks off this week, challenging talent to deliver real solutions to the healthcare market.

Today, the U.S. Food and Drug Administration cleared a mobile medical application (app) to help increase retention (the amount of time a patient participates) in an outpatient treatment program for individuals with opioid use disorder (OUD). The reSET-O app is a prescription cognitive behavioral therapy intended to be used in addition to outpatient treatment under the care of a health care professional,

German Accelerator Life Sciences Alumni company, SpinDiag, just announced the successful closing of 3 million Series A funding round. The Freiburg-based health tech startup addresses the challenge of patients introducing drug-resistant bacteria into hospitals. SpinDiag provides a rapid point-of-care screening system, SpinDiag one, to test high-risk patients for all relevant drug-resistances.

Bayer announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition, which Bayer is currently developing jointly with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA).

Two pioneering NHS organisations have been recognised at the 2018 HTN Awards for their innovative work using InterSystems technology to help transform care for patients. The judges, who included GPs and clinical commissioning group IT leads, as well as project managers, clinical leads and IT directors from acute trusts and mental health and community providers, selected Coordinate My Care and North Tees and Hartlepool NHS Foundation Trust as winners.

At the Congress of the Radiological Society of North America (RSNA 2018) in Chicago, USA, Siemens Healthineers is presenting AI-Pathway Companion* for the first time. It is a clinical decision support system based on artificial intelligence that supports physicians in making diagnostic and therapeutic decisions along the clinical pathway.

Merck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syntropy. Syntropy is expected to empower scientists and research centers with a collaborative technology platform to advance cancer research, help drive scientific discovery, and improve human lives.